Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal NEO100 in Pediatric-type High Grade Gliomas
NCT06357377Phase 1Recruiting
- Sponsor
- NeOnc Technologies Holdings, Inc.
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of NEO100-02 in high-grade glioma (HGG), diffuse midline glioma (DMG), choroid plexus carcinoma (CPC) and 2 more (4 cohorts), sponsored by NeOnc Technologies Holdings, Inc. Primary endpoint: Adverse Events at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
NEO100-02
03
Conditions
high-grade glioma (HGG)diffuse midline glioma (DMG)choroid plexus carcinoma (CPC)pineoblastoma (PB)central nervous system embryonal tumor
Beyond the preview
Go deeper on NCT06357377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357377.